Clifford Chance | Pharma companies and antitrust in China: Part two – anti-competitive behaviour, abuse of dominance and enforcement trends

1 July 2011

Pharma companies and antitrust in China: Part two – anti-competitive behaviour, abuse of dominance and enforcement trends

Antitrust & competition, Antitrust competition litigation, China, Corporate advice, Joint ventures & strategic alliances, Pharmaceuticals, Private acquisitions & disposals, Public takeovers & mergers, Trade
Glen Ma, Ninette Dodoo, Yong Bai
Client Briefing

Download File

Pharma companies and antitrust in China: Part two – anti-competitive behaviour, abuse of dominance and enforcement trends

Related Papers

Pharma companies and antitrust in China: Part one - merger clearance

In this second of two articles exploring the impact of China's antitrust regime on the pharmaceutical industry, we consider in more detail how the day-to-day operations of pharmaceutical companies are affected by China's competition regime, and highlight certain commercial practices that may attract the attention of the enforcement authorities.

Download Full Report